Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions. Building upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies, the Company is progressing innovative approaches to the treatment of diseases with high unmet medical need. Our strategy is to establish proof of concept in rare diseases and then expand into more common diseases. Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Our scientific founders and advisors include leaders in mitochondrial biology, metabolism and aging with experience in translating novel discoveries into next-generation medicines. The Company was founded in October of 2013 with financing from MPM Capital, Longwood Fund, and Astellas Pharma and a shared vision for the promise of mitochondrial-targeted therapeutics. In January of 2018, the Company was acquired by Astellas Pharma.